Related Experiment Video
Updated: Sep 25, 2025
Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
Published on: July 6, 2019
Arbutin Alleviates LPS Induced Sepsis Pneumonia in Mice
Xiang-Xiang Bian1, Xuan Zhao1, Chun-Hua Ma2
1School of Pharmacy, Anhui Medical University, Hefei 230032, China.
Abstract:
The aim of this study was to investigate the effects of arbutin (AR) on lipopolysaccharide (LPS)-induced sepsis pneumonia. LPS-induced mice and A549 cells were used to establish septic pneumonia model. AR significantly decreased lung wet-to-dry weight (W/D) ratio, lung myeloperoxidase (MPO) activity and ameliorated lung histopathological changes. In addition, AR increased super oxide dismutase (SOD) activity, decreased malondialdehyde (MDA) content and levels of cytokines including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-β) and interleukin-6 (IL-6) in bronchoalveolar lavage fluid (BALF) in mice. Furthermore, the results demonstrated that AR inhibited the JAK2/STAT3/NF-κB pathway in LPS-induced A549 cells which was further confirmed by siRNA JAK2 experiment. The experimental results indicated that the protective mechanism of AR on sepsis pneumonia might be attributed partly to the inhibition of cytokine production and JAK2/STAT3/NF-κB pathway.
Insights
Arbutin (AR) effectively treats sepsis pneumonia by reducing lung damage and inflammation. It works by inhibiting the JAK2/STAT3/NF-κB pathway, offering a potential therapeutic strategy.
Area of Science:
- Pharmacology
- Immunology
- Cell Biology
Background:
- Sepsis pneumonia is a severe condition with significant lung damage.
- Lipopolysaccharide (LPS) is a key inducer of inflammatory responses in sepsis.
- Arbutin (AR) is a compound with potential therapeutic properties.
Purpose of the Study:
- To investigate the protective effects of arbutin (AR) against lipopolysaccharide (LPS)-induced sepsis pneumonia.
- To elucidate the underlying molecular mechanisms of AR's action.
- To evaluate AR's impact on oxidative stress and inflammatory markers.
Main Methods:
- Establishment of a sepsis pneumonia model using LPS-induced mice and A549 cells.
- Assessment of lung injury markers: wet-to-dry weight ratio (W/D) and myeloperoxidase (MPO) activity.
- Measurement of antioxidant enzyme activity (superoxide dismutase, SOD) and lipid peroxidation (malondialdehyde, MDA).
- Quantification of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in bronchoalveolar lavage fluid (BALF).
- Investigation of the JAK2/STAT3/NF-κB signaling pathway, including siRNA JAK2 experiments.
Main Results:
- Arbutin significantly reduced lung W/D ratio, MPO activity, and improved lung histopathology.
- AR increased SOD activity and decreased MDA content, indicating reduced oxidative stress.
- AR treatment lowered levels of TNF-α, IL-1β, and IL-6 in BALF.
- Arbutin inhibited the JAK2/STAT3/NF-κB pathway in LPS-induced A549 cells.
Conclusions:
- Arbutin demonstrates significant protective effects against LPS-induced sepsis pneumonia.
- The therapeutic mechanism of AR involves the inhibition of pro-inflammatory cytokine production.
- Arbutin's protective action is partly attributed to the suppression of the JAK2/STAT3/NF-κB signaling pathway.
